Clinical trial
LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
NCT01649284 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- July 31, 2012
- Completion date
- March 31, 2014
- Enrollment
- Not reported
- Sites
- 66
Conditions
As the registry lists them; a condition with its own page is linked.